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Introduction: We urgently need novel treatments for multidrug-resistant tuberculosis (MDR-TB). Autolo- 
gous mesenchymal stromal cell (MSC) infusion is one such possibility due to its potential to repair dam- 
aged lung tissue and boost immune responses. We aimed to assess the effectiveness of MSC to improve 
outcomes among MDR-TB patients. 
Methods: We analyzed outcomes for 108 Belarussian MDR-TB patients receiving chemotherapy. Thirty- 
six patients (“cases”) also had MSCs extracted, cultured and re-infused (average time from chemotherapy 
start to infusion was 49 days); another 36 patients were “study controls”. We identiﬁed another control 
group: 36 patients from the Belarussian surveillance database (“surveillance controls”) 1:1 matched to 
cases. 
Results: Of the cases, 81% had successful outcomes versus 42% of surveillance controls and 39% of study 
controls. Successful outcome odds were 6.5 (95% Conﬁdence Interval: 1.2–36.2, p = 0.032) times greater 
for cases than surveillance controls (age-adjusted). Radiological improvement was more likely in cases 
than study controls. Culture analysis prior to infusion demonstrated a poorer initial prognosis in cases, 
yet despite this they had better outcomes than the control groups. 
Conclusion: MSC treatment could vastly improve outcomes for MDR-TB patients. Our ﬁndings could revo- 
lutionize therapy options and have strong implications for future directions of MDR-TB therapy research. 
© 2016 The Authors. Published by Elsevier Ltd. 
This is an open access article under the CC BY-NC-ND license 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ). 
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2. Introduction 
Despite recent reductions in tuberculosis (TB) incidence and
ortality [1] , slow progress is threatened by emerging drug resis-
ant strains, responsible for 480,0 0 0 multidrug-resistant TB (MDR-∗ Corresponding author at: Department of Biostatistics, Boston University School 
f Public Health, 801 Massachusetts Avenue, Boston, MA 02118, USA 
E-mail addresses: aliaksandr_skrahin@tut.by (A. Skrahin), jenkins.helen@ 
mail.com (H.E. Jenkins), niipulm@tut.by (H. Hurevich), varvaras@tut.by 
(V. Solodovnikova), yaninai@mail.ru (Y. Isaikina), darktheatro@gmail.com 
(D. Klimuk), z_o_y_i.r@rambler.ru (Z. Rohava), alena.skrahina@gmail.com 
(A. Skrahina). 
1 These authors contributed equally. 
2 Present address: Department of Biostatistics, Boston University School of Public 
ealth, 801 Massachusetts Avenue, Boston, MA 02118, USA. 
r  
o  
n  
[
 
o  
B  
t  
d  
t  
ttp://dx.doi.org/10.1016/j.jctube.2016.05.003 
405-5794/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article uB; TB strains resistant to isoniazid and rifampin) cases in 2013
1] . Current MDR-TB drugs are more toxic and have to be taken for
onger than those for drug susceptible TB [2] ; successful outcome
ates are poorer [3] and only around half of treated MDR-TB cases
lobally are cured or complete treatment successfully [1,4] . Cur-
ently, the development of anti-tuberculosis drugs lags behind that
f Mycobacterium tuberculosis drug resistance. We urgently need
ovel treatment options to improve outcomes for MDR-TB cases
5] . 
Belarus, in Eastern Europe, has the highest reported percentage
f TB cases with MDR-TB in the world (45.5% of all TB cases in
elarus have MDR-TB) [6] and less than 50% of these patients are
reated successfully (as per the World Health Organization [WHO]
eﬁnition, treated successfully includes those cured and completed
reatment with no evidence of failure of treatment) [4] . In 2009,nder the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ). 
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t  a pilot study began in Belarus to assess the safety and effective-
ness of autologous mesenchymal stromal cell (MSC) infusion as
adjunct treatment in MDR-TB patients [7] . Although host-directed
therapies have been hailed as a breakthrough for cancer [8] , new
concepts and clinically relevant trials are needed to achieve similar
life-changing progress in infectious diseases. 
The study motivation came from evidence that MSCs can facil-
itate organ homoeostasis and repair damaged lung tissue [9] . Ad-
ditionally, it is possible that immunotherapeutic methods could re-
duce high inﬂammatory immune response in TB [10] with MSCs
being one such potential method [11] . In the pilot study, the MSC
treatment was found to be safe [7] . Here, we use these Phase I trial
data to obtain a preliminary assessment of the MSC treatment ef-
fectiveness and give an indication of the potential value of Phase
II/III trials. 
2. Methods 
We conducted an observational study using (1) outcome data
from a non-randomised controlled trial in Belarus, and (2) data
collected from the Belarussian surveillance database. 
2.1. Patient recruitment to the trial 
An ongoing open-label phase I non-randomized controlled trial
of MSC infusion as adjunct treatment in MDR-TB patients has been
conducted since September 2009 at the Republican Research and
Practical Centre for Pulmonology and TB (RRPCPTB), Minsk, Be-
larus [7] . This includes those with extensively drug resistant TB
(XDR-TB; MDR-TB plus resistance to an injectable drug and a ﬂu-
oroquinolone), those with “pre-XDR-TB” (MDR-TB plus resistance
to either an injectable or a ﬂuoroquinolone) and MDR-TB patients
without additional resistance. Seventy-two patients have been re-
cruited: 36 that agreed to receive the MSC therapy (“cases”) and
36 that did not agree to the treatment but consented to the mon-
itoring necessary for the study (“study controls”). The main in-
clusion criteria were pulmonary TB conﬁrmed by culture; MDR-,
pre-XDR- or XDR-TB conﬁrmed by drug susceptibility testing; age
between 18 and 65 years; and absence of lesion compatible with
a malignant process or ongoing tuberculosis in organs other than
lungs and pleura [7] . Individuals with the following co-morbidities
were also excluded: HIV, hepatitis B and/or C, autoimmune dis-
eases, multi-organ failure, sepsis (any bacterial sepsis), abscess for-
mation other than TB etiology, cancer and other malignancies, anti-
DNA antibodies, allergies and any other disease that researchers
believed was clinically signiﬁcant and could affect the study re-
sults or cause an additional risk to the patient. Participants were
not compensated for taking part in the study or for their travel ex-
penses. Full details of this study are available elsewhere [7] and in
the Appendix. 
2.2. Selection of alternative controls from surveillance data 
Since the study was non-randomized, there was potential for
differences between cases and study controls that could have in-
ﬂuenced the apparent MSC treatment effectiveness. Therefore, for
a parallel analysis we selected matched controls (“surveillance con-
trols”) from the Belarussian TB surveillance database. Brieﬂy, this
database contains all reported TB cases in Belarus since 2009 and
their demographic and clinical data. We 1:1 matched cases to
controls (who met the original study inclusion criteria [7] ) from
the surveillance database on: (1) drug resistance proﬁle (MDR-TB,
pre-XDR-TB or XDR-TB), (2) previous TB treatment history ( < one
month of treatment (“new”) or ≥one month of treatment (“pre-
viously treated”)) and (3) baseline smear microscopy status (posi-
tive/negative). Previously treated patients in the trial were furthertratiﬁed into “previously treated” (previous treatment(s) with ﬁrst
ine drugs and/or less than two treatments with second line drugs)
nd “chronic” ( ≥2 previous second line regimens) but surveillance
ontrols were not stratiﬁed in this way, due to lack of information
egarding the number of times they had previously received treat-
ent. Matching criteria were selected after reviewing the base-
ine differences between cases and study controls. We randomly
elected surveillance controls although patients from Minsk city
ere prioritised due to logistical diﬃculties elsewhere in obtain-
ng matching and potential confounder data. 
.3. Treatment and monitoring 
All patients received an individualized optimal background reg-
men throughout their treatment period in accordance with WHO
uidelines [12] (Appendix Table S1-3). In addition, bone marrow
spirates of 40–80 mL were obtained from the iliac crest of the
ases, MSCs were isolated, cultured, prepared for infusion and re-
nfused on average 49 days after chemotherapy initiation, as de-
cribed previously [7] . The entire MSC cell dose was given as a
low (5 min) bolus injection via a peripheral intravenous line. 
For cases and study controls, chest X-rays were taken at
hemotherapy initiation and approximately eight months later to
ssess changes. X-rays were assessed by experienced radiologists,
ho were blind to treatment, and scored as per Ralph et al.
13] (brieﬂy, the score equals the percentage of lung involvement,
lus 40 if cavities are present). Adverse event information among
ases and study controls was collected during the ﬁrst six months
fter MSC infusion and six months corresponding period (starting
ne month after chemotherapy initiation) for the study controls. 
Microbiological data were collected from patient medical
ecords or from reporting systems for National TB control pro-
ram. The RRPCPTB received External Quality Assurance from the
wedish Institute for Infectious Disease Control throughout the
tudy period. TB was conﬁrmed with direct microscopy after
iehl–Neelsen staining and culture and drug susceptibility testing
ere done using the BACTEC MGIT 960 system (Becton Dickinson,
parks, MD, USA). 
.4. Baseline characteristics 
We compared the baseline characteristics of cases with each
ontrol group using a t -test (for continuous variables) or Fisher’s
xact test (for categorical variables). Since the patient’s choice to
eceive the MSC treatment may have been associated with hard to
uantify factors such as motivation to be cured or general knowl-
dge about and desire for optimal health, we examined poten-
ial proxies for these factors (smoking, employment, education and
arital status). 
.5. Analysis of outcomes 
All outcome deﬁnitions were consistent with the 2008 WHO
uidelines [12] for MDR-TB patients (2008 guidelines used because
he original trial began in 2009). 
Successful outcomes included “cured” and “treatment com-
leted” and all other outcomes were “unsuccessful” (e.g. death,
reatment failure, treatment default/lost to follow-up). “Cured” is
eﬁned as treatment completed as recommended by the national
olicy without evidence of failure and ﬁve or more consecutive
ultures taken at least 30 days apart negative in the ﬁnal 12
onths of treatment. “Treatment completed” is deﬁned as treat-
ent completed as recommended by the national policy without
vidence of failure but with fewer than ﬁve cultures performed in
he ﬁnal 12 months of treatment. Both of these categories consist
A. Skrahin et al. / Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 4 (2016) 21–27 23 
Table 1 
Baseline characteristics. Baseline characteristics of patients that received the MSC treatment (“cases”), controls selected for the study (“study controls”) and controls 
selected from surveillance data (“surveillance controls”). 
Variable Cases ( N = 36) Study controls 
( N = 36) 
Surveillance 
controls 
( N = 36) 
p -Value for difference (cases 
versus study controls 
p -Value for difference 
(cases versus 
surveillance controls) 
Age, mean (SD) 30.5 (8.5) 38.8 (13.9) 44.1 (10.9) 0.004 < 0.0 0 01 
Gender, n , (% male) 18 (50.0%) 25 (69.4%) 31 (86.1%) 0.15 0.002 
Treatment history 
New case, n (%) 13 (36.1%) 19 (52.8%) 13 (36.1%) 0.077 1.00 a 
Previously treated case, n (%) 11 (30.6%) 13 (36.1%) 23 (63.9%) b 
Chronic case, n (%) 12 (33.3%) 4 (11.1%) 
Drug resistance proﬁle 
MDR, n (%) 9 (25.0%) 20 (55.6%) 9 (25.0%) 
Pre-XDR, n (%) 12 (33.3%) 10 (27.8%) 12 (33.3%) 0.020 1.00 a 
XDR, n (%) 15 (41.7%) 6 (16.7%) 15 (41.7%) 
Smear positive at start of 
chemotherapy, n (%) 
5 (13.9%) 18 (50.0%) 5 (13.9%) 0.002 1.00 a 
Current smoker, n (%) 20 (55.6%) 25 (69.4%) 26 (72.2%) 0.33 0.22 
Employment status 
Unemployed, n (%) 5 (13.9%) 13 (36.1%) 3 (8.3%) 
Employed, n (%) 18 (50.0%) 13 (36.1%) 23 (63.9%) 
On disability beneﬁts, n (%) 6 (16.7%) 4 (11.1%) 7 (19.4%) 0.030 0.11 
Student, n (%) 5 (13.9%) 1 (2.8%) 0 (0.0%) 
Maternity leave/housewife, n (%) 2 (5.6%) 1 (2.8%) 1 (2.8%) 
Retired, n (%) 0 (0.0%) 4 (11.1%) 2 (0.0%) 
Marital status 
Single, n (%) 17 (47.2%) 20 (55.6%) 16 (44.4%) 
Married, n (%) 18 (50.0%) 13 (36.1%) 16 (44.4%) 0.49 0.50 
Divorced, n (%) 1 (2.8%) 2 (5.6%) 4 (11.1%) 
Widowed, n (%) 0 (0.0%) 1 (2.8%) 0 (0.0%) 
Highest education level 
Secondary school, n (%) 9 (25.0%) 11 (30.6%) 5 (13.9%) 
College, n (%) 17 (47.2%) 17 (47.2%) 22 (61.1%) 
Currently at university, n (%) 5 (13.9%) 1 (2.8%) 0 (0.0%) 0.060 0.040 
University, n (%) 5 (13.9%) 2 (5.6%) 9 (25.0%) 
No data, n (%) 0 (0.0%) 5 (13.9%) 0 (0.0%) 
a Controls were matched to MSC patients on these variables. 
b Chronic and previously treated patients were all grouped as previously treated patients in the surveillance database. 
o  
d
 
t  
c  
s  
u  
c  
t  
t  
e  
t  
c  
t  
c  
w  
u  
c  
g  
o
 
t
2
a
 
g  
t  
e  
u
2
 
c  
s  
c  
f  
a
2
 
p  
f  
p  
s
 
d  
C  
a  
a
3
3
 
C  
t  
T  
s  f patients that are clinically cured of TB, the difference is in the
egree of bacteriological evidence. 
We examined the percentage of cases and each control group
hat had a successful outcome within each stratum of the baseline
haracteristics to check for consistency in outcomes rates across
trata. When comparing outcomes in cases and study controls, we
sed logistic regression to model the odds of a successful out-
ome and a conditional logistic regression when comparing cases
o surveillance controls to account for the 1:1 matching. All po-
ential explanatory variables were entered into the model as cat-
gorical variables, other than age, which was entered as a con-
inuous variable. In both, a binary, explanatory variable deﬁned
ase/control status of the patient. Due to the relatively small pa-
ient numbers and resulting potential for model instability, we
ould not adjust for all potential confounders simultaneously. Since
e aimed to produce MSC treatment effect estimates, we produced
nivariable regression estimates of the odds of a successful out-
ome among cases versus controls and a series of bivariable re-
ression models to assess the effect of each potential confounder
n the treatment estimate. 
As a sub-analysis, we used sputum culture conversion as an al-
ernative endpoint (Appendix methods). 
.6. Percentage of patients that were culture positive at two, four 
nd six months 
We calculated the number and percentage of patients in each
roup whose sputum converted to culture negative status after
wo, four and six months of treatment. We compared the differ-
nces between these percentages in each group, at each time point,
sing Fisher’s exact test. .7. Analysis of radiology 
The percentage change in X-ray score was calculated and
lassed as improved ( ≥10% decrease), worsened ( ≥5% increase) or
table otherwise [7] . We compared the number of cases and study
ontrols that had an improved or worsened radiology score at
ollow-up using Fisher’s exact test. Radiology data were not avail-
ble for surveillance controls. 
.8. Adverse events 
We compared the number of cases and study controls that ex-
erienced each adverse event using Fisher’s exact test, adjusting
or multiple testing using a Bonferroni correction [14] (see Ap-
endix). Information on adverse events was not available for the
urveillance controls. 
Statistical analyses of non-identiﬁable data from the described
atasets were deemed exempt by Partners Healthcare Research
ommittee (the IRB for Partners Healthcare on behalf of Brigham
nd Women’s Hospital), Boston, MA. HEJ carried out all statistical
nalyses. 
. Results 
.1. Comparison of baseline characteristics 
Cases and study controls differed substantially at baseline.
ases were more likely to be chronic than new patients compared
o study controls ( p = 0.07) and were more likely to have pre-XDR-
B or XDR- TB ( p = 0.02) ( Table 1 ). Cases were less likely to be
mear microscopy positive (13.9% versus 50.0%; p = 0.002). Study
24 A. Skrahin et al. / Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 4 (2016) 21–27 
Table 2 
Outcomes for MSC recipients (cases), study controls and matched surveillance controls. 
Cases ( n = 36) Study controls ( n = 36) Surveillance controls ( n = 36) 
Successful outcomes: 29 (81%) 14 (39%) 15 (42%) 
Cured 27 (75%) 8 (22%) 8 (22%) 
Treatment completed 2 (6%) 6 (17%) 7 (19%) 
Unsuccessful outcomes: 7 (19%) 22 (61%) 21 (58%) 
Death 0 (0%) 0 (0%) 4 (11%) 
Default/lost to follow-up 1 (3%) 6 (17%) 5 (14%) 
Treatment failure 6 (17%) 16 (44%) 12 (33%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Sputum culture conversion during treatment . The percentage of patients that 
converted to culture negative status at two, four and six months after start of 
chemotherapy treatment. Data are shown for cases (white bars), study controls 
(pale grey bars) and surveillance controls (dark grey bars). Data at four months 
were not available for the surveillance controls. p -Values shown are for the dif- 
ferences between the cases and each of the control groups at each time point for 
which data were available. 
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a  controls were more likely to be unemployed ( p = 0.03) and less
likely to have attained university level education ( p = 0.06). 
Surveillance controls were, on average, older than cases (mean
age = 44.1 years versus 38.8 years, p < 0.0 0 01) and were more
likely to be male (86.1% male versus 50.0%, p = 0.002) ( Table 1 ).
Surveillance controls were more likely than cases to have attained
university level education ( p = 0.04) and were somewhat less likely
to be unemployed ( p = 0.11). 
3.2. Analysis of outcomes 
Among cases, 29 (81%) patients had a successful outcome
( Table 2 ). Six (17%) patients failed treatment and one (3%) de-
faulted on treatment. Among the study controls, 14 (39%) patients
had a successful outcome. Sixteen (44%) failed treatment and six
(17%) defaulted or were lost to follow up. Among the surveillance
controls, 15 (42%) had a successful outcome, four (11%) died, ﬁve
(14%) defaulted or were lost to follow up and 12 (33%) failed treat-
ment. 
The percentage of outcomes that was successful among cases
was consistently higher than among either of the control groups,
across almost all strata of the baseline characteristics ( Table 3 ). The
exceptions were chronic TB patients and those on disability (two
almost entirely overlapping groups). 
When assessing successful outcome odds, we used the compari-
son with the surveillance controls as our main analysis (since they
were more similar to cases at baseline than the study controls).
After adjusting for age (the only negative confounder of those we
could assess), cases had odds of a successful outcome 6.5 (95%
Conﬁdence Interval: 1.2–36.2) times greater than the surveillance
controls ( p = 0.032) ( Table 4 ). 
Results of the comparison with study controls and sputum cul-
ture conversion analysis supported these results (Appendix Tables
S4 and S5). 
3.3. Culture negative status at two, four and six months 
Two months after chemotherapy start, fewer cases had con-
verted to culture negative status than study controls (5.7% ver-
sus 27.3%, p -Value = 0.053) or surveillance controls (5.7% versus
38.9%, p -Value = 0.010) ( Fig. 1 ). At four months, 60.6% of cases
had culture converted compared with 43.8% of the study controls
(four month data were unavailable for surveillance controls). At six
months, 71.9% of cases had converted compared with 58.6% of the
study controls and 71.4% of the surveillance controls ( p -Values both
> 0.05 for differences). 
3.4. Analysis of radiology 
Twenty-ﬁve cases showed improvement in their radiology score
compared with 15 study controls ( p = 0.032 for the difference).
Four cases had a worsened radiology score compared with nine
study controls ( p = 0.22). .5. Adverse events 
The most common adverse events among cases were hyperc-
olesterolaemia and nausea (Appendix Table S6). There were no
igniﬁcant differences in the adverse event rate between cases and
tudy controls. 
. Discussion 
This study is, to our knowledge, the ﬁrst to estimate the eﬃcacy
f any cellular therapy for M/XDR-TB. With 81% of MSC recipients
xperiencing a successful outcome as compared with 39% or 42%
n the control groups, the effect appears striking. 
Several biological mechanisms can explain the improved out-
omes observed. The MSC clinical eﬃcacy can be explained by a
eduction of inﬂammation-induced damage [11] ; treatments to tar-
et overt inﬂammatory responses have shown clinical beneﬁts [15] .
hosphodiesterase inhibitors [16,17] with anti-TNF α effects have
een tested in safety trials and drugs such as etanercept or inﬂix-
mab were effective as adjunctive therapy in animal models [18] .
he overall eﬃcacy of prednisolone and dexamethasone resulted
n improved survival in TB meningitis patients (17% reduction in
ortality across 41 clinical trials) [15] . 
MSC can be involved in other important immune mecha-
isms: MSC stimulation with inﬂammatory cytokines has induced
 broad range of antimicrobial effector functions mediated by the
A. Skrahin et al. / Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 4 (2016) 21–27 25 
Table 3 
Number and percentage of patients with a successful outcome (cured or completed treatment at ﬁrst recording of an outcome) stratiﬁed by potential confounders. 
Variable Cases ( n = 36) Study controls ( n = 36) p -Value ∗ comparing 
cases with study 
controls 
Surveillance controls 
( n = 36) 
p -Value ∗ comparing 
cases with 
surveillance 
controls 
Age 
< 35 years old 20/25 (80.0%) 8/17 (47.1%) 0.045 3/8 (37.5%) 0.036 
35 years or older 9/11 (81.8%) 6/19 (31.6%) 0.021 12/28 (42.9%) 0.038 
Gender 
Males 13/18 (72.2%) 4/11 (36.4%) 0.12 15/31 (48.4%) 0.14 
Females 16/18 (88.9%) 10/25 (40.0%) 0.002 0/5 (0.0%) 0.006 
Treatment history 
New case 13/13 (100.0%) 8/19 (42.1%) 0.001 6/13 (46.2%) 0.005 
Previously treated case 10/11 (80.9%) 4/13 (30.8%) 0.005 9/23 (39.1%) 0.075 
Chronic case 6/12 (50.0%) 2/4 (50.0%) > 0.99 
Drug resistance proﬁle 
MDR 9/9 (100.0%) 9/20 (45.0%) 0.005 3/9 (33.3%) 0.009 
Pre-XDR 9/12 (75.0%) 5/10 (50.0%) 0.38 8/12 (66.7%) > 0.99 
XDR 11/15 (73.3%) 0/6 (0.0%) 0.004 4/15 (26.7%) 0.027 
Smear status at start of 
chemotherapy 
Positive 3/5 (60.0%) 5/18 (27.8%) 0.30 2/5 (40.0%) > 0.99 
Negative 26/31 (83.9%) 9/18 (50.0%) 0.020 13/31 (41.9%) 0.001 
Current smoker 
Yes 15/20 (75.0%) 10/25 (40.0%) 0.034 10/26 (38.5%) 0.019 
No 14/16 (87.5%) 4/11 (36.4%) 0.012 5/10 (50.0%) 0.069 
Employment status 
Unemployed 4/5 (80.0%) 2/13 (15.4%) 0.022 1/3 (33.3%) 0.49 
Employed 16/18 (88.9%) 5/13 (38.5%) 0.006 11/23 (47.8%) 0.008 
On disability beneﬁts 3/6 (50.0%) 2/4 (50.0%) > 0.99 2/7 (28.6%) 0.59 
Student 4/5 (80.0%) 1/1 (100.0%) > 0.99 0/0 N/A 
Maternity leave/housewife 2/2 (100.0%) 1/1 (100.0%) > 0.99 0/1 (0.0%) 0.33 
Retired 0/0 3/4 (75.0%) N/A 1/2 (50.0%) N/A 
Marital status 
Single 12/17 (70.6%) 8/20 (40.0%) 0.10 8/16 (50.0%) 0.30 
Married 16/18 (88.9%) 5/13 (38.5%) 0.006 7/16 (43.8%) 0.009 
Divorced 1/1 (100.0%) 1/2 (50.0%) > 0.99 0/4 (0.0%) 0.20 
Widowed 0/0 0/1 (0.0%) N/A 0/0 N/A 
Highest education level 
Secondary school 5/9 (55.6%) 4/11 (36.4%) 0.65 2/5 (40.0%) > 0.99 
College 15/17 (88.2%) 7/17 (41.2%) 0.010 8/22 (36.4%) 0.001 
Currently at university 4/5 (80.0%) 1/1 (100.0%) > 0.99 0/0 N/A 
University 5/5 (100.0%) 1/2 (50.0%) 0.29 5/9 (55.6%) 0.22 
No data 0/0 1/5 (20.0%) N/A 0/0 N/A 
∗ p -Values show the result of Fisher’s exact test, testing the null hypothesis that successful outcome rates are equal between cases and controls. A p -Value less than 
0.05 indicates evidence of a statistically signiﬁcant difference in the percentages of cases and control with successful outcomes. 
Table 4 
Results of univariable and bivariable conditional logistic regression modeling the odds of a successful outcome. The control group 
used here are the surveillance controls 1:1 matched to cases on (a) drug resistance proﬁle, (b) smear status at start of chemother- 
apy and (c) previous treatment status. Differences in the odds ratios illustrate the confounding effects of each variable on the 
estimated odds ratio of the MSC treatment on outcomes. 
Model Variable Odds ratio (95% CI) p -Value 
Univariable Case versus control 7.77 (1.78, 33.81) 0.006 
Bivariable: adjusting for age a Case versus control 6.51 (1.17, 36.22) 0.032 
Age, for each additional year 0.98 (0.90, 1.08) 0.73 
Bivariable: adjusting for gender Case versus control 12.54 (1.61, 97.91) 0.016 
Gender, male versus female 2.86 (0.27, 30.31) 0.38 
Bivariable: adjusting for current smoker Case versus control 10.37 (1.53, 70.07) 0.016 
Current smoker, yes versus no 0.17 (0.01, 2.54) 0.20 
Bivariable: adjusting for employment status Case versus control 7.76 (1.78, 33.78) 0.006 
Employed versus all other categories b 0.95 (0.13, 6.95) 0.96 
Bivariable: adjusting for marital status Case versus control 12.29 (1.68, 89.78) 0.013 
Married versus single/divorced 0.24 (0.02, 2.54) 0.24 
Case versus control 11.26 (1.61, 78.95) 0.015 
Bivariable: adjusting for education level College/university versus secondary school 3.37 (0.22, 50.93) 0.38 
a Age was entered into the model as a continuous variable. 
b Categories for employment status included in “other” were: unemployed, on disability beneﬁts, student, on maternity 
leave/housewife and retired. 
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c  tryptophan catabolising enzyme indoleamine 2,3-dioxygenase [19] ;
MSCs act by reduction of oxidative stress, which was shown to be
operational in a murine model of acute coxsackievirus B3-induced
myocarditis [20] ; enhanced phagocytosis was, in part, responsible
for increased bacterial clearance and improved survival in a murine
sepsis model [21] and ﬁnally, MSC possess direct antimicrobial ac-
tivity, which is mediated by the secretion of human cathelicidin
hCAP-18/ LL-37 [22] . 
Several studies have shown that MSCs exhibited therapeutic po-
tential in preclinical models of acute lung injury [23] , endotoxin-
[24] and bleomycin-induced lung injury [25] , associated with de-
creased expression of transforming growth factor β1 responsible
for pulmonary ﬁbrosis [26] . In addition, lung tissue regeneration
capacity of MSC has been shown previously [27,28] . There have
been other in vivo studies of MSC for lung disease. For example,
the START trial was a Phase I trial of intravenous MSCs in pa-
tients with Acute Respiratory Distress Syndrome (ARDS). This study
showed that MSCs were well-tolerated in the nine patients and the
authors have now proceeded to Phase II testing [29] . There was
another, separate, pilot study of MSCs in patients with ARDS that
also found that they were well-tolerated, although the clinical ef-
fect was weak [30] . MSCs have also been studied in patients with
Chronic Obstructive Pulmonary Disease (COPD) and have also been
shown to be well-tolerated in these patients [31] . 
MSC can be engrafted into the lungs and differentiated into
various types of lung cells: alveolar type I and type II cells
[27,32] airway epithelium cells [33,34] and endothelial cells [32] .
In addition, MSC can restore lung epithelium via donation of mi-
tochondria to other cells [33] and increase the proliferative po-
tential of bronchoalveolar stem cells [34] . In animal model ex-
periments a large fraction of systemically (intravenously) infused
MSC typically become trapped within the lungs owing to their
large size and their repertoire of cell-surface adhesion receptors
[35–38] . Real-time PCR analysis for human-speciﬁc Alu sequences
in blood samples showed that within 5 min of MSC infusion
through the tail vein, 99% of MSC were cleared from the circula-
tion. Within 10–30 min, a resurgence of ∼2–3% of the infused MSC
was observed within the blood stream. Tissue samples from vari-
ous organs revealed that the majority of cells were initially found
in the lung, which is consistent with previous studies. Then, 15 min
after infusion, 83% of the human DNA was detected in the lung,
whereas only trace amounts were detected in other tissues [39] .
Plate-adherent cultured bone marrow cells (i.e. MSCs), when given
intravenously in wild-type mice following bleomycin-induced lung
injury, engrafted into the recipient lung parenchyma with a mor-
phological and molecular phenotype of alveolar type I pneumo-
cytes [27] . Human umbilical cord MSC when cultured in vitro with
specialized growth medium/growth factors expressed Clara cell se-
cretory protein (CCSP), surfactant protein C (SPC) and cystic ﬁbrosis
transmembrane conductance regulator (CFTR). After systemic ad-
ministration to immunotolerant, NOD-SCID mice, cells were local-
ized in the lung airway epithelium that expressed cytokeratin and
human CFTR [28] . Wong et al. found a subpopulation of adherent
human and murine bone marrow cells (currently called MSC) that
expressed CCSP, and when cultured ex vivo with an air-liquid in-
terface, these CCSP + cells expressed alveolar type I and II mark-
ers such as pro-SPC, CFTR and epithelial sodium channel (ENaC).
CCSP + cells preferentially homed to naphthalene-damaged airways
when delivered transtracheally or intravenously [40,41] . 
Our study has some limitations. When comparing cases to
study controls, the patient recruitment method could have biased
the resulting eﬃcacy estimate. Patients choosing the treatment
may be exceptionally motivated to be cured and thus more likely
to have a positive outcome than a randomly selected MDR-TB pa-
tient. This motivation may be reﬂected in their lifestyle choices
and their adherence to chemotherapy, which could inﬂuence theirutcome. To account for this, we sought out additional informa-
ion as a proxy for these factors and analysis adjusting for these
ata showed no change in the overall conclusion (Appendix Table
4). The treatment effect was maintained when comparing with
atched controls from the Belarussian surveillance data, even af-
er adjusting for the only identiﬁable negative confounder ( Table
 ). Therefore, it seems unlikely that confounding factors can fully
xplain the observed treatment effect. However, our results may
ot be generalizable to patients with different characteristics from
hose studied here. In particular, there were very low numbers of
ases with smear-positive disease; further studies of MSC treat-
ent should ensure recruitment of suﬃcient numbers of smear-
ositive individuals. 
Other unmeasureable baseline differences between cases and
urveillance controls might explain the observed treatment effect.
owever, a greater proportion of surveillance controls had con-
erted to culture negative status at two months after chemother-
py start than cases. At this point, some MSC patients had yet to
eceive the infusion and many had only very recently received it
average receipt of infusion was 49 days after chemotherapy start).
herefore, given the documented association between two-month
ulture conversion and successful treatment outcome [42,43] , we
ould expect the cases to experience poorer outcomes than the
urveillance controls. However, at four and six months, having all
eceived the infusion some time previously, there were very similar
roportions of cases that were culture negative as among surveil-
ance controls and the cases experienced better outcomes. This
attern was consistent when comparing cases to study controls.
hese data are consistent with the hypothesis that the baseline
haracteristics of the cases cannot fully explain the improved out-
omes observed in this group and instead something external (e.g.
he MSC treatment) occurred to change the trajectory of these
atients. In addition, radiology analysis showed that signiﬁcantly
ore of the cases showed improvements than study controls. 
Our study may have been under-powered to detect a difference
n adverse events between the groups. Further studies should be
uﬃciently powered and randomized to identify any increase in
dverse events experienced by MSC recipients. 
The current treatment situation for M/XDR-TB cases is dire.
nly 20% of the estimated global incident MDR-TB cases in 2013
ere successfully diagnosed and started on appropriate treatment
1] . Although some countries have documented relatively high
ates of successful outcomes [44] (around 70%), many countries
uccessfully treat less than half of their treated M/XDR-TB cases
4] . Our results demonstrate that MSC could revolutionize out-
omes for individuals with MDR-TB. With patients dying from
/XDR-TB daily, randomized, controlled trials of MSC infusion are
rgently needed to conﬁrm these ﬁndings so that patients can start
eneﬁtting from this novel treatment. 
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